



## New share issue oversubscribed

Meda's new share has been completed and it was subscribed at 120 percent. Through the new share issue, Meda will raise SEK 1,511 million before issue costs.

*"Meda's new share issue financed the recent strategic acquisitions and despite the turmoil on the financial markets the share issue was significantly oversubscribed. That is very satisfying and we appreciate the confidence",* said Anders Lönner, CEO Meda.

99.35 percent of the shares offered in the new share issue were subscribed for with preferential subscription rights. In accordance with the principles described in the prospectus, the 280,338 Class A shares which were not subscribed for with subscription rights (corresponding to 0.65 percent of the total number of shares offered) will be allotted to shareholders who subscribed for shares without subscription rights. As the new share issue is fully subscribed for, the underwriting guarantee does not need to be utilised.

As a result of the new share issue, the number of shares in the company increases with 43,177,580 shares through the issue of 43,177,580 new Class A shares. The share capital of Meda increases with SEK 43,177,580. After the new share issue, the share capital amounts to SEK 302,243,065 distributed among 302,243,065 Class A-shares. The new issued Class A shares are scheduled to become subject to trading at the OMX Nordic Exchange Stockholm during December 2008.

Danske Markets is the financial advisor of Meda in connection with the new share issue.

---

For more information contact:

Anders Larnholt, VP Investor Relations

Phone. +46 709 458 878

**MEDA Aktiebolag (publ)** is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Exchange Stockholm. Find out more, visit [www.meda.se](http://www.meda.se).

*The publication or distribution of this press release may in certain jurisdictions be subject to restrictions by law and persons in such jurisdictions where this press release has been made public or distributed should inform themselves about such restrictions and act accordingly.*

*This press release may not be announced, published or distributed, directly or indirectly, to or in the United States of America, Canada, Australia, Hong Kong, Japan or in any other country where such measure wholly or partly is subject to restrictions by law. The information in this press release may not be forwarded, reproduced or shown in way that is in conflict with such restrictions. Failure to comply with this instruction may constitute a violation of the United States Securities Act of 1933 ("Securities Act") or applicable laws in other jurisdictions.*

*The information in this press release has been made public according to the Securities and Market Act and the Financial Instruments Trading Act. This information was published on 28 November 2008.*